Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women’s and general health, eye health, gastrointestinal diseases, and toxicology worldwide. More Details
Flawless balance sheet with solid track record.
Share Price & News
How has Quidel's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: QL1 is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: QL1's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: QL1 underperformed the German Medical Equipment industry which returned 41.5% over the past year.
Return vs Market: QL1 underperformed the German Market which returned 42.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Quidel's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Quidel undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: QL1 (€103.05) is trading above our estimate of fair value (€102.14)
Significantly Below Fair Value: QL1 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: QL1 is good value based on its PE Ratio (6.6x) compared to the DE Medical Equipment industry average (46.3x).
PE vs Market: QL1 is good value based on its PE Ratio (6.6x) compared to the German market (28.2x).
Price to Earnings Growth Ratio
PEG Ratio: QL1's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: QL1 is good value based on its PB Ratio (4x) compared to the DE Medical Equipment industry average (7.9x).
How is Quidel forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: QL1's earnings are forecast to decline over the next 3 years (-8.5% per year).
Earnings vs Market: QL1's earnings are forecast to decline over the next 3 years (-8.5% per year).
High Growth Earnings: QL1's earnings are forecast to decline over the next 3 years.
Revenue vs Market: QL1's revenue is expected to decline over the next 3 years (-8.4% per year).
High Growth Revenue: QL1's revenue is forecast to decline over the next 3 years (-8.4% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: QL1's Return on Equity is forecast to be low in 3 years time (7.9%).
How has Quidel performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: QL1 has a high level of non-cash earnings.
Growing Profit Margin: QL1's current net profit margins (48.8%) are higher than last year (13.7%).
Past Earnings Growth Analysis
Earnings Trend: QL1 has become profitable over the past 5 years, growing earnings by 86.3% per year.
Accelerating Growth: QL1's earnings growth over the past year (1008.6%) exceeds its 5-year average (86.3% per year).
Earnings vs Industry: QL1 earnings growth over the past year (1008.6%) exceeded the Medical Equipment industry 44.3%.
Return on Equity
High ROE: QL1's Return on Equity (60.8%) is considered outstanding.
How is Quidel's financial position?
Financial Position Analysis
Short Term Liabilities: QL1's short term assets ($1.1B) exceed its short term liabilities ($337.0M).
Long Term Liabilities: QL1's short term assets ($1.1B) exceed its long term liabilities ($201.5M).
Debt to Equity History and Analysis
Debt Level: QL1 is debt free.
Reducing Debt: QL1 has no debt compared to 5 years ago when its debt to equity ratio was 65.6%.
Debt Coverage: QL1 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: QL1 has no debt, therefore coverage of interest payments is not a concern.
What is Quidel current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate QL1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate QL1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if QL1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if QL1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of QL1's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Doug Bryant (62 yo)
Mr. Douglas C. Bryant, also known as Doug, has been the Chief Executive Officer and President of Quidel Corp. since March 1, 2009. Mr. Bryant served as the Chief Operating Officer and Executive Vice Presid...
CEO Compensation Analysis
Compensation vs Market: Doug's total compensation ($USD4.17M) is about average for companies of similar size in the German market ($USD3.26M).
Compensation vs Earnings: Doug's compensation has increased by more than 20% in the past year.
Experienced Management: QL1's management team is considered experienced (3.5 years average tenure).
Experienced Board: QL1's board of directors are considered experienced (4.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: QL1 insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Quidel Corporation's company bio, employee growth, exchange listings and data sources
- Name: Quidel Corporation
- Ticker: QL1
- Exchange: DB
- Founded: 1979
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$5.485b
- Listing Market Cap: US$4.597b
- Shares outstanding: 42.32m
- Website: https://www.quidel.com
Number of Employees
- Quidel Corporation
- 9975 Summers Ridge Road
- San Diego
- United States
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women’s and general health, eye health, gastrointestinal di...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/14 17:31|
|End of Day Share Price||2021/04/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.